Four Decades for Justice
Cravath’s broad‑based intellectual property practice has deep experience advising clients ranging from early‑stage startups to global companies in corporate contexts across the full spectrum of intellectual property disciplines, technologies and jurisdictions. Our corporate IP practice is distinctive for its “cross‑disciplinary and highly collaborative approach,” placing Cravath “a class apart” for providing “integrated solutions to the most pressing legal and business problems faced by industry leaders.” (IAM Patent 1000)
Cravath’s IP lawyers work hand in glove with our premier corporate practices to handle the many intellectual property issues that arise in complex transactions, including issues relating to patents, trademarks, copyrights, data, trade secrets, privacy and information security. We also advise on matters in connection with emerging technologies, including artificial intelligence and fintech solutions involving Web3/blockchain, digital assets, smart contracts and decentralized networks.
Our IP lawyers bring a great depth of technical and scientific backgrounds to provide expert advice related to:
Cravath also provides strategic counseling, review and analysis in developing and managing intellectual property portfolios, commercializing innovation‑based assets and optimizing intellectual property rights to ensure our clients are maximizing value from their intellectual property in the U.S. and in non-U.S. markets.
Cravath helps clients navigate AI and data issues with respect to data ownership and licensing, business operations and disputes related to AI and data, as well as the acquisition of data and AI technologies. Our expertise across subject areas allows us to provide interdisciplinary advice on AI and data issues, including ownership of and rights to use AI algorithms and related data, confidentiality management and related transaction structuring.
Cravath advises on a wide variety of data security and privacy issues across the whole spectrum of transactions and projects, including data collection, data storage, multi‑party data arrangements and agreements, such as between data controllers and/or data processors, cross‑border data sharing, protection of personally identifiable and other sensitive information, and privacy and data protection compliance matters, including advising on privacy policies and privacy notices and other privacy compliance requirements under the GDPR and other relevant regimes.
Cravath’s IP lawyers work hand in glove with our premier corporate practices to handle the many intellectual property issues that arise in complex transactions, including issues relating to patents, trademarks, copyrights, data, trade secrets, privacy and information security. We also advise on matters in connection with emerging technologies, including artificial intelligence and fintech solutions involving Web3/blockchain, digital assets, smart contracts and decentralized networks.
Our IP lawyers bring a great depth of technical and scientific backgrounds to provide expert advice related to:
Cravath also provides strategic counseling, review and analysis in developing and managing intellectual property portfolios, commercializing innovation‑based assets and optimizing intellectual property rights to ensure our clients are maximizing value from their intellectual property in the U.S. and in non-U.S. markets.
Cravath helps clients navigate AI and data issues with respect to data ownership and licensing, business operations and disputes related to AI and data, as well as the acquisition of data and AI technologies. Our expertise across subject areas allows us to provide interdisciplinary advice on AI and data issues, including ownership of and rights to use AI algorithms and related data, confidentiality management and related transaction structuring.
Cravath advises on a wide variety of data security and privacy issues across the whole spectrum of transactions and projects, including data collection, data storage, multi‑party data arrangements and agreements, such as between data controllers and/or data processors, cross‑border data sharing, protection of personally identifiable and other sensitive information, and privacy and data protection compliance matters, including advising on privacy policies and privacy notices and other privacy compliance requirements under the GDPR and other relevant regimes.
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Deals & Cases
February 12, 2024
On February 12, 2024, Martin Marietta Materials, Inc. (“Martin Marietta”) announced that on February 11, 2024, it entered into a definitive agreement to acquire 20 active aggregates operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia from affiliates of Blue Water Industries LLC (“BWI Southeast”) for $2.05 billion in cash. Additionally, on February 9, 2024, Martin Marietta completed its previously announced divestiture of its South Texas cement and related concrete operations to CRH Americas Materials, Inc., a subsidiary of CRH plc, for $2.1 billion in cash. Cravath is representing Martin Marietta in connection with the transactions.
Deals & Cases
February 06, 2024
On February 6, 2024, altafiber, provider of integrated communications solutions over its fiber‑optic network to residential and business customers in Ohio, Kentucky, and Indiana, and TowerBrook Capital Partners (“TowerBrook”), the New York and London‑based international investment firm, announced that TowerBrook has agreed to acquire CBTS, a leading North American provider of IT solutions and services, from altafiber. Cravath is representing altafiber in connection with the transaction.
Deals & Cases
February 01, 2024
On February 1, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has expanded its interest in royalties on the U.S. net sales of Omidria® by amending its existing agreement with Omeros Corporation ("Omeros") for $115 million on closing and up to $55 million in potential sales‑based milestone payments. As a result, the Trust will now receive 100% of Omeros’s royalties on the U.S. net sales of Omidria® through December 31, 2031. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Activities & Publications
March 18, 2024
On March 14, 2024, Cravath hosted its 2024 Web3 Regulatory Forum at its offices in New York. The event brought together lawyers from the Firm, market participants, executives, investors and others for presentations by practitioners, current and former regulators, and interactive roundtables examining the most significant regulatory developments in the digital assets and Web3 space.
Activities & Publications
March 05, 2024
On March 5, 2024, Cravath partner David J. Kappos participated in “Preserving U.S. Leadership in Biopharmaceutical Innovation,” an event hosted by the Information Technology and Innovation Foundation in Washington, D.C. Dave and other experts spoke alongside the Honorable Paul R. Michel, former Chief Judge of the U.S. Court of Appeals for the Federal Circuit, about why the U.S. may have lost its lead in advanced technology industries, including telecommunications equipment, and how policymakers can support cutting‑edge innovation and avoid repeating the same mistakes in the biopharmaceutical sector.
Activities & Publications
February 14, 2024
Cravath partners G.J. Ligelis Jr., Alyssa K. Caples, Christopher K. Fargo and Margaret T. Segall co‑authored the U.S. Law & Practice chapter of the fourth edition of Chambers “Investing In… 2024” Guide, which was published in January 2024. The guide, which is part of the publisher’s Global Practice Guides series, examines country‑specific legal issues that arise from foreign direct investment (“FDI”) and cross‑border transactions in the more than 30 jurisdictions covered. The U.S. Law & Practice chapter surveys the legal system and regulatory framework for FDI in the country, analyzing the economic climate, as well as considerations related to mergers and acquisitions, corporate governance, capital markets, antitrust, national security, tax, employment and intellectual property.
Activities & Publications
February 12, 2024
In February 2024, Cravath continued its “Tech Explainers” series, which introduces and explains technical, cutting‑edge concepts and describes their importance in a way that is accessible to and easily understood by business and legal professionals outside the technical community.
Activities & Publications
February 05, 2024
Cravath partner Sasha Rosenthal‑Larrea and associates Daniel M. Barabander and Lucille Dai‑He co‑authored an article entitled “Summarization and ChatGPT: A Look at Silverman v. OpenAI,” which was published to the website of Thomson Reuters Westlaw on February 2, 2024. The article discusses how AI summarization functions and the questions it continues to raise on the bounds of copyright law, including in Silverman v. OpenAI, an ongoing case in the U.S. District Court for the Northern District of California.
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Deals & Cases
February 12, 2024
On February 12, 2024, Martin Marietta Materials, Inc. (“Martin Marietta”) announced that on February 11, 2024, it entered into a definitive agreement to acquire 20 active aggregates operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia from affiliates of Blue Water Industries LLC (“BWI Southeast”) for $2.05 billion in cash. Additionally, on February 9, 2024, Martin Marietta completed its previously announced divestiture of its South Texas cement and related concrete operations to CRH Americas Materials, Inc., a subsidiary of CRH plc, for $2.1 billion in cash. Cravath is representing Martin Marietta in connection with the transactions.
Deals & Cases
February 06, 2024
On February 6, 2024, altafiber, provider of integrated communications solutions over its fiber‑optic network to residential and business customers in Ohio, Kentucky, and Indiana, and TowerBrook Capital Partners (“TowerBrook”), the New York and London‑based international investment firm, announced that TowerBrook has agreed to acquire CBTS, a leading North American provider of IT solutions and services, from altafiber. Cravath is representing altafiber in connection with the transaction.
Deals & Cases
February 01, 2024
On February 1, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has expanded its interest in royalties on the U.S. net sales of Omidria® by amending its existing agreement with Omeros Corporation ("Omeros") for $115 million on closing and up to $55 million in potential sales‑based milestone payments. As a result, the Trust will now receive 100% of Omeros’s royalties on the U.S. net sales of Omidria® through December 31, 2031. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Activities & Publications
March 18, 2024
On March 14, 2024, Cravath hosted its 2024 Web3 Regulatory Forum at its offices in New York. The event brought together lawyers from the Firm, market participants, executives, investors and others for presentations by practitioners, current and former regulators, and interactive roundtables examining the most significant regulatory developments in the digital assets and Web3 space.
Activities & Publications
March 05, 2024
On March 5, 2024, Cravath partner David J. Kappos participated in “Preserving U.S. Leadership in Biopharmaceutical Innovation,” an event hosted by the Information Technology and Innovation Foundation in Washington, D.C. Dave and other experts spoke alongside the Honorable Paul R. Michel, former Chief Judge of the U.S. Court of Appeals for the Federal Circuit, about why the U.S. may have lost its lead in advanced technology industries, including telecommunications equipment, and how policymakers can support cutting‑edge innovation and avoid repeating the same mistakes in the biopharmaceutical sector.
Activities & Publications
February 14, 2024
Cravath partners G.J. Ligelis Jr., Alyssa K. Caples, Christopher K. Fargo and Margaret T. Segall co‑authored the U.S. Law & Practice chapter of the fourth edition of Chambers “Investing In… 2024” Guide, which was published in January 2024. The guide, which is part of the publisher’s Global Practice Guides series, examines country‑specific legal issues that arise from foreign direct investment (“FDI”) and cross‑border transactions in the more than 30 jurisdictions covered. The U.S. Law & Practice chapter surveys the legal system and regulatory framework for FDI in the country, analyzing the economic climate, as well as considerations related to mergers and acquisitions, corporate governance, capital markets, antitrust, national security, tax, employment and intellectual property.
Activities & Publications
February 12, 2024
In February 2024, Cravath continued its “Tech Explainers” series, which introduces and explains technical, cutting‑edge concepts and describes their importance in a way that is accessible to and easily understood by business and legal professionals outside the technical community.
Activities & Publications
February 05, 2024
Cravath partner Sasha Rosenthal‑Larrea and associates Daniel M. Barabander and Lucille Dai‑He co‑authored an article entitled “Summarization and ChatGPT: A Look at Silverman v. OpenAI,” which was published to the website of Thomson Reuters Westlaw on February 2, 2024. The article discusses how AI summarization functions and the questions it continues to raise on the bounds of copyright law, including in Silverman v. OpenAI, an ongoing case in the U.S. District Court for the Northern District of California.
Explore
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.